- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02264028
Metabolism and Pharmacokinetics of [14C]-DK-AH 269 CL in 12 Healthy Male Volunteers
13. Oktober 2014 aktualisiert von: Boehringer Ingelheim
Metabolism and Pharmacokinetics of [14C]-DK-AH 269 CL After Administration of Single Doses of 5 mg [14C]-DK-AH 269 CL Intravenously and 10 mg [14C]-DK-AH 269 CL as Oral Solution in a Parallel-group Design in 12 Healthy Male Volunteers
- To investigate absorption, metabolism and excretion of [14C]-DK-AH 269 CL after oral and intravenous administration in healthy volunteers
- To assess the safety and tolerability of DK-AH 269 CL after oral and intravenous administration to healthy volunteers
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Tatsächlich)
12
Phase
- Phase 1
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
50 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Männlich
Beschreibung
Inclusion Criteria:
- 50 to 65 years of age
- Body Mass Index (BMI) of 19.9 to 29.9 kg/m2
- Resting heart rate (HR) (after 5 min. in the supine position) of more than 55 bpm
- All volunteers will have given their written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation.
Exclusion Criteria:
- Any finding at the medical examination (including BP, HR and ECG) deviating from normal and of clinical relevance
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, hematological/oncological, immunological or hormonal disorders
- Diseases of the central nervous system or psychiatric disorders or neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- Intake of drugs with a long half-life (> 24 hours) within ten half-lives of the respective drug before enrolment in the study
- Use of any drugs which might influence the results of the trial within two weeks prior to administration or during the trial
- Participation in another trial with an investigational drug (≤ two months prior to administration or during the trial)
- Smoker (> 10 cigarettes or > 3 cigars of > 3 pipes/day)
- Inability to refrain from smoking on trial days
- Alcohol abuse (> 60 g/day)
- Drug abuse
- Blood donation (≥ 100 mL within 2 months prior to administration or during the trial)
- Excessive physical activities (within the last week before the study)
- Any laboratory value outside the reference range and of clinical relevance
- Inability to comply with dietary regimen of study centre
Not necessarily clinically relevant abnormalities, but specific exclusion criteria for the drugs under study or for the study:
- Subjects at increased risk for development of cardiac arrhythmia (e.g. family history of long QT syndrome or sudden cardiac death)
- ECG: PR interval > 210 ms
- HR at rest ≤ 55 beats per minute (bpm)
- Relevant ophthalmological disease
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: [14C]-DK-AH 269 CL intravenous
|
|
Experimental: [14C]-DK-AH 269 CL oral
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Maximum measured concentration of the analytes in plasma (Cmax)
Zeitfenster: Up to 96 hours after start of treatment
|
Up to 96 hours after start of treatment
|
|
Area under the concentration-time curve of the analytes in plasma (AUC)
Zeitfenster: Up to 96 hours after start of treatment
|
Up to 96 hours after start of treatment
|
|
Time from dosing to the maximum concentration of the analytes in plasma (tmax)
Zeitfenster: Up to 96 hours after start of treatment
|
Up to 96 hours after start of treatment
|
|
Terminal rate constant of the analytes in plasma (λz)
Zeitfenster: Up to 96 hours after start of treatment
|
Up to 96 hours after start of treatment
|
|
Terminal half-life of the analytes in plasma (t1/2)
Zeitfenster: Up to 96 hours after start of treatment
|
Up to 96 hours after start of treatment
|
|
Mean residence time of the analytes in the body after intravenous administration (MRT)
Zeitfenster: Up to 96 hours after start of treatment
|
Up to 96 hours after start of treatment
|
|
Mean residence time of the analytes in the body after oral administration (MRTpo)
Zeitfenster: Up to 96 hours after start of treatment
|
Up to 96 hours after start of treatment
|
|
Apparent clearance of the analytes in plasma following extravascular administration (CL/F)
Zeitfenster: Up to 96 hours after start of treatment
|
Up to 96 hours after start of treatment
|
|
Total clearance of the analytes in plasma following intravascular administration (CL)
Zeitfenster: Up to 96 hours after start of treatment
|
Up to 96 hours after start of treatment
|
|
Apparent volume of distribution of the analytes during the terminal phase λz following extravascular administration (Vz/F)
Zeitfenster: Up to 96 hours after start of treatment
|
Up to 96 hours after start of treatment
|
|
Volume of distribution at steady state (Vss)
Zeitfenster: Up to 96 hours after start of treatment
|
Up to 96 hours after start of treatment
|
|
Fraction of analytes eliminated in urine from 0 to the time of the last quantifiable data point (fe0-tz)
Zeitfenster: Up to 120 hours after start of treatment
|
Up to 120 hours after start of treatment
|
|
Fraction of analytes eliminated in faeces from 0 to the time of the last quantifiable data point (fefaeces,0-tz)
Zeitfenster: Up to 120 hours after start of treatment
|
Up to 120 hours after start of treatment
|
|
Renal clearance of the analytes from 0 to the time of the last quantifiable data point (CLR,0-tz)
Zeitfenster: Up to 120 hours after start of treatment
|
Up to 120 hours after start of treatment
|
|
Fraction of dose absorbed, based on radioactivity data (Fa)
Zeitfenster: Up to 96 hours after start of treatment
|
Up to 96 hours after start of treatment
|
|
Absolute bioavailability of the analytes after oral administration (F)
Zeitfenster: Up to 96 hours after start of treatment
|
Up to 96 hours after start of treatment
|
|
Ratio of CBlood cells/Cplasma [14C]-radioactivity
Zeitfenster: Up to 96 hours after start of treatment
|
Up to 96 hours after start of treatment
|
|
Number of patients with clinically significant findings in vital signs
Zeitfenster: up to 12 days after last drug administration
|
blood pressure, heart rate
|
up to 12 days after last drug administration
|
Number of patients with clinically significant findings in 12-lead ECG
Zeitfenster: up to 12 days after last drug administration
|
up to 12 days after last drug administration
|
|
Number of patients with clinically significant findings in 2-lead ECG (telemetry)
Zeitfenster: up to 90 minutes after start of treatment
|
up to 90 minutes after start of treatment
|
|
Clinically significant changes from baseline in physical examination
Zeitfenster: Pre-dose, and 12 days after last drug administration
|
Pre-dose, and 12 days after last drug administration
|
|
Occurrence of visual phenomena
Zeitfenster: up to 120 hours after start of treatment
|
questionnaire
|
up to 120 hours after start of treatment
|
Number of patients with clinically significant findings in clinical laboratory tests
Zeitfenster: up to 12 days after last drug administration
|
up to 12 days after last drug administration
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Nützliche Links
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. März 2004
Primärer Abschluss (Tatsächlich)
1. April 2004
Studienanmeldedaten
Zuerst eingereicht
13. Oktober 2014
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
13. Oktober 2014
Zuerst gepostet (Schätzen)
15. Oktober 2014
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
15. Oktober 2014
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
13. Oktober 2014
Zuletzt verifiziert
1. Oktober 2014
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 503.209
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .